RWM
LGND icon

Raffa Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Raffa Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11
Closed -$850 – 338
2017
Q2 		$850 Hold
11
– – ﹤0.01% 369
2017
Q1 		$741 Hold
11
– – ﹤0.01% 356
2016
Q4 		$711 Buy
+11
New +$694 ﹤0.01% 571

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Raffa Wealth Management's LGND Position: Q3 2017 in Review

Raffa Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2017, closing a stake of 11 shares — an estimated $850 sold.

Raffa Wealth Management first reported a position in LGND in Q4 2016 and held it in 3 quarters. The position peaked at $850 in Q2 2017. 293 funds tracked by Wall St. Rank hold LGND as of Q3 2017.

  • Raffa Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Raffa Wealth Management sold 11 Ligand Pharmaceuticals shares in Q3 2017, an estimated $850.
  • Raffa Wealth Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Raffa Wealth Management's Ligand Pharmaceuticals position peaked at $850 in Q2 2017.
  • 293 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2017.

Based on Raffa Wealth Management's 13F filing for Q3 2017, filed 27 Jul 2026.